PredictCan Biotechnologies has been recognized by innovation intelligence firm StartUs Insights as one of five exemplary startups shaping the future of precision medicine. The selection was made following an analysis of more than 600 companies worldwide as part of the Precision Medicine Market Report 2025.
PredictCan was highlighted for its AI-enabled Cell Educating Technology™, which brings human biological diversity into preclinical drug development through individualized, patient-centric models. By combining human serum-derived educated spheroids with microphysiological systems and advanced data analysis, the platform is designed to capture interindividual differences in drug response that conventional standardized models may overlook.
Bringing Precision Medicine into Preclinical Drug Development
PredictCan’s approach enables the generation of standardized yet individualized 3D models, providing robust datasets for the assessment of drug efficacy and toxicity across diverse human biological backgrounds. These data can subsequently support AI-driven analyses aimed at identifying differential responses, susceptible populations, and biological patterns associated with drug response.
The technology was highlighted by StartUs Insights for its potential applications across drug development, personalized medicine, and biomarker discovery. Its scalable microphysiological approach also enables multiple individualized models to be evaluated in parallel, opening the possibility of studying drug response at the population level before entering clinical trials.
Toward More Predictive and Inclusive Drug Development
This recognition reinforces PredictCan’s mission to move precision medicine upstream—from the clinic into preclinical development. By accounting for human biological diversity earlier in the development process, PredictCan aims to help pharmaceutical and biotechnology companies better understand which compounds are most promising, which populations may benefit, and which individuals may be at greater risk of toxicity.
Ultimately, PredictCan’s ambition is to contribute to a new generation of preclinical models that combine human relevance, biological diversity, reproducibility, and scalability, supporting safer, more predictive, and more inclusive drug development.
